What is NON RARE IN EUROPE: Hyperlipoproteinemia type 4?
Hyperlipoproteinemia type 4, also known as familial hypertriglyceridemia or type IV hyperlipidemia, is a condition where the blood contains too much of a type of fat called triglycerides. Triglycerides are a normal part of your blood, but when levels get too high, they can cause serious health problems. This condition is labeled 'non-rare in Europe,' meaning it is actually quite common compared to most rare diseases listed on Orphanet. In this condition, the liver makes too many particles called VLDL (very low-density lipoprotein), which carry triglycerides through the bloodstream. Over time, high triglyceride levels can damage blood vessels and increase the risk of heart disease and pancreatitis (a painful inflammation of the pancreas). Many people have no obvious symptoms at first, which is why it is often discovered during routine blood tests. Treatment focuses on lowering triglyceride levels through lifestyle changes like diet and exercise, as well as medications such as fibrates, niacin, and omega-3 fatty acids. With proper management, most people can significantly reduce their risk of complications and live a normal life. Regular monitoring by a doctor is important to keep levels under control.
Key symptoms:
High triglyceride levels found on a blood testFatty deposits under the skin called xanthomas (yellowish bumps, especially on elbows, knees, or buttocks)Abdominal pain, especially after eating fatty foodsPancreatitis (severe stomach pain caused by inflammation of the pancreas)Fatigue and low energyEnlarged liver or spleenCreamy or milky appearance of blood when drawnIncreased risk of heart diseaseBlurry vision in some casesNausea or vomiting
- Inheritance
- Multifactorial
- Caused by a mix of several genes and environmental factors
- Age of Onset
- Adult
- Begins in adulthood (age 18 or older)
FDA & Trial Timeline
1 eventRegion Stockholm — NA
Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for NON RARE IN EUROPE: Hyperlipoproteinemia type 4.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
Specialists
View all specialists →Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
No specialists are currently listed for NON RARE IN EUROPE: Hyperlipoproteinemia type 4.
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to NON RARE IN EUROPE: Hyperlipoproteinemia type 4.
Community
No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Hyperlipoproteinemia type 4.
Start the conversation →Latest news about NON RARE IN EUROPE: Hyperlipoproteinemia type 4
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for NON RARE IN EUROPE: Hyperlipoproteinemia type 4.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What triglyceride level should I aim for, and how often should I get blood tests?,Which dietary changes will have the biggest impact on my triglyceride levels?,Do I need medication right away, or should I try lifestyle changes first?,What are the signs of pancreatitis, and when should I go to the emergency room?,Should my family members be tested for this condition?,Are there any medications I currently take that could be making my triglycerides worse?,What is my overall cardiovascular risk, and do I need additional heart-related tests?
Common questions about NON RARE IN EUROPE: Hyperlipoproteinemia type 4
What is NON RARE IN EUROPE: Hyperlipoproteinemia type 4?
Hyperlipoproteinemia type 4, also known as familial hypertriglyceridemia or type IV hyperlipidemia, is a condition where the blood contains too much of a type of fat called triglycerides. Triglycerides are a normal part of your blood, but when levels get too high, they can cause serious health problems. This condition is labeled 'non-rare in Europe,' meaning it is actually quite common compared to most rare diseases listed on Orphanet. In this condition, the liver makes too many particles called VLDL (very low-density lipoprotein), which carry triglycerides through the bloodstream. Over time,
How is NON RARE IN EUROPE: Hyperlipoproteinemia type 4 inherited?
NON RARE IN EUROPE: Hyperlipoproteinemia type 4 follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does NON RARE IN EUROPE: Hyperlipoproteinemia type 4 typically begin?
Typical onset of NON RARE IN EUROPE: Hyperlipoproteinemia type 4 is adult. Age of onset can vary across affected individuals.
Are there clinical trials for NON RARE IN EUROPE: Hyperlipoproteinemia type 4?
Yes — 1 recruiting clinical trial is currently listed for NON RARE IN EUROPE: Hyperlipoproteinemia type 4 on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Frequently asked questions about NON RARE IN EUROPE: Hyperlipoproteinemia type 4
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is NON RARE IN EUROPE: Hyperlipoproteinemia type 4?
NON RARE IN EUROPE: Hyperlipoproteinemia type 4 is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:413). It is typically inherited as multifactorial. Age of onset is generally adult. For verified primary sources, see the UniteRare NON RARE IN EUROPE: Hyperlipoproteinemia type 4 page.
How is NON RARE IN EUROPE: Hyperlipoproteinemia type 4 inherited?
NON RARE IN EUROPE: Hyperlipoproteinemia type 4 follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for NON RARE IN EUROPE: Hyperlipoproteinemia type 4?
Approved treatments for NON RARE IN EUROPE: Hyperlipoproteinemia type 4 are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials recruiting for NON RARE IN EUROPE: Hyperlipoproteinemia type 4?
UniteRare currently lists 1 clinical trial relevant to NON RARE IN EUROPE: Hyperlipoproteinemia type 4 sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.
How do I find a specialist for NON RARE IN EUROPE: Hyperlipoproteinemia type 4?
Verified NON RARE IN EUROPE: Hyperlipoproteinemia type 4 specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.
See full NON RARE IN EUROPE: Hyperlipoproteinemia type 4 page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.